Peregrine Investment Management’s Beam Therapeutics BEAM Stock Holding History

Peregrine Investment Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Sell	70,000 -190,050	-73%	-$5.74M	1.02%	26
2026 Q1	$6.2M	Buy	260,050 +2,770	+1%	+$76.9K	4.87%	13
2025 Q4	$7.13M	Sell	257,280 -10,650	-4%	-$272K	4.43%	14
2025 Q3	$6.5M	Buy	267,930 +3,670	+1%	+$73K	3.19%	16
2025 Q2	$4.5M	Buy	264,260 +40,000	+18%	+$697K	2.87%	18
2025 Q1	$4.38M	Buy	224,260 +65,710	+41%	+$1.72M	3.27%	16
2024 Q4	$3.93M	Buy	+158,550	New	+$4.05M	2.28%	22

Other funds holding BEAM

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BEI

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

GITFIT

Generali Investments Towarzystwo Funduszy Inwestycyjnych (TFI) Warsaw, Poland $249M AUM 37.04% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

MMA

Miracle Mile Advisors Los Angeles, California $8.53B AUM 21.43% 1-Year Est. Return

Peregrine Investment Management's BEAM Position: Q2 2026 in Review

Peregrine Investment Management reduced its Beam Therapeutics (BEAM) stake by 73% in Q2 2026, selling an estimated $5.74M and leaving 70,000 shares worth $2.4M. The position accounts for 1.02% of the portfolio, ranked #26.

Peregrine Investment Management first reported a position in BEAM in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.13M in Q4 2025. 38 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Peregrine Investment Management held 70,000 shares of Beam Therapeutics worth $2.4M as of Q2 2026.
Peregrine Investment Management sold 190,050 Beam Therapeutics shares in Q2 2026, an estimated $5.74M.
Beam Therapeutics made up 1.02% of Peregrine Investment Management's portfolio in Q2 2026, its #26 holding.
Peregrine Investment Management first reported a position in Beam Therapeutics in Q4 2024 and has held it in 7 quarters since.
Peregrine Investment Management's Beam Therapeutics position peaked at $7.13M in Q4 2025.
38 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Peregrine Investment Management's 13F filing for Q2 2026, filed 23 Jul 2026.